Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2006 / N 3

Особенности и механизмы действия аторвастатина: взгляд биолога (часть I) (Список литературы)
В.А. Метельская

Список литературы
1. Malhorta HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidemia. Drugs 2001; 61:1835-81.
2. Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005; 96 (Suppl): 11F-23F.
3. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006.
4. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol 2003; 92: 670-76.
5. Olsson AG, Eriksson M, Johnson O, et al., 3T Study Investigators. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. Clin Ther. 2003;25:119-38.
6. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low density lipoprotein cholesterol goals with five statins Am J Med 2001; 111: 185-91.
7. Davidson M, McKehhey J, Stein E, et al. Comparison of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79:1475-81.
8. Jones P, Kafonek S, Laurora I, et al. Comparative Dose Efficacy Study of Atorvastatin vs Simvastatin, Pravastatin, Lovastatin, Fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cariol 1998; 81: 582-7.
9. Dg S. The cost-effectiveness of statins: evidence from the ACCESS trial. Value in Health 2004; 4:108-9.
10. Sever PS, Dahlof B, Poulter NR, et al; ASCOT Investigators. Prevetion of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the ASCOT-LLA: a multicentre randomized controlled trial. Lancet 2003; 631: 1149-58.
11. LaRosa JC, Grundy SM. Intensive lipid lowering with atorvastatin in patients with stabile coronary disease. The TNT Study. N Engl J Med 2005; 352: 1425-35.
12. Pedersen TR, Faergeman O, Holme I, et al. Effect of greater LDL-C reductions on prognosis – The IDEAL trial. JAMA 2005; 294: 1437-45.
13. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80.
14. Okazaki S, Yokoyama T, Miyauchi K et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004;110 (9):1061-8.
15. Cannon CP, Braunwald E, McCabe CH, et al. PROVE IT-TIMI 22 Trial. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
16. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled study. JAMA 2001; 285:1711-8.
17. Isaacsohn JL, Davidson MH, Hunninghake D, et al. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol 2000; 86: 250-2.
18. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering in atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001; 357: 577-81.
19. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-6.
20. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for Reduction of Myocardial Damage during coronary intervention (ARMYDA). Circulation 2004;110: 674-8.
21. Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women. Circulation 2005; 112: 563-71.
22. McPherson R, Angus C, Murray P, Genest J Jr. Efficacy of atorvastatin in achieving NCEP LDL targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women'sAtorvastatin Trial on Cholesterol (WATCH). Am Heart J 2001;141: 949-56.
23. Deedwandia PC, for the SAGR Steering Committee. Study Assessing Goals in the Elderly. Am Heart J 2004; 148:1053-9.
24. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet 2004; 364: 685-96.
25. Wanner C, Krane V, Marz W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study). Kidney&Blood Pressure Res 2004; 27:259-66.
26. Insull W, Kafonek S, Dalley WL, et al. The efficacy and safety of atorvastatin versus simvastatin in patients with and without type 2 diabetes. Diabetologia 2000; 43 (Suppl 1): 288:1105.
27. Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H. DALI Study group. Diabetes Care 2004; 27: 1358-64.
28. De Sutter J, De Bacquer D, Jordaens L, et al. Intensive lipid-lowering therapy and ventricular arrhythmias in patients with coronary artery disease and internal cardioverter defibrillators. Abstr. Heart Rhythm Society Scientific Sessions; May 17-20, 2006; Boston, MA, USA.
29. Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 332-7.
30. Packard C. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. Atherosclerosis 2006; Suppl 7: 21-9.
31. Barter P. HDL: a recipe for longevity. Atherosclerosis 2004; Suppl 5: 25-31.
32. Kastelein JP, Stein ES, Davidson MA, et al. Simvastatin increases HDL-C and apolipoprotein AI levels significantly more than atorvastatin. J Am Coll Cardiol 2000; 35 (Suppl A): 1009-173.
33. Crouse JR, Fronlich J, Ose L, et al. Effects of high doses of simvastatin versus atrovastatin on high-density lipoprotein cholesterol and apolipoprotein AI. Am J Cardiol 1999;83:1476-7.
34. Перова НВ, Озерова ИН, Метельская ВА. Метаболическая система выведения холестерина из тканей. Возможность активации ее ключевых звеньев РФК2006; № 2: 49-56.
35. LaRosa JC. Prevention and treatment of coronary heart disease: who benefits? Circulation 2001; 104: 1688-92.
36. Cannon CP, Steiberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate therapy. J Am Coll Cardiol 2006; 48: 438-45.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]